Comprehensive review of glucagon-like peptide 1 receptor agonist treatment on the risk of cardiovascular outcomes and retinopathy as diabetic complications.
糖尿病併發症中胰高血糖素樣肽-1受體激動劑治療對心血管結果和視網膜病變風險的全面回顧。
Eur Rev Med Pharmacol Sci 2023-05-03
Incretins and microvascular complications of diabetes: neuropathy, nephropathy, retinopathy and microangiopathy.
胰高血糖素和糖尿病微血管併發症:神經病變、腎病變、視網膜病變和微血管病變。
Diabetologia 2023-09-28
Associations of antidiabetic drugs with diabetic retinopathy in people with type 2 diabetes: an umbrella review and meta-analysis.
抗糖尿病藥物與2型糖尿病患者糖尿病視網膜病變的關聯:一項綜述和荟萃分析。
Front Endocrinol (Lausanne) 2024-03-20
Novel Antidiabetic Drugs and the Risk of Diabetic Retinopathy: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.
新型抗糖尿病藥物與糖尿病視網膜病變風險:隨機對照試驗的系統性回顧和荟萃分析。
J Clin Med 2024-03-30
Risk of diabetic retinopathy and diabetic macular oedema with sodium-glucose cotransporter 2 inhibitors and glucagon-like peptide 1 receptor agonists in type 2 diabetes: a real-world data study from a global federated database.
二型糖尿病患者使用鈉葡萄糖共同轉運蛋白2抑制劑和葡萄糖依賴性胰高血糖素樣肽1受體激動劑的視網膜病變和糖尿病黃斑水腫風險:來自全球聯合數據庫的實證研究。
Diabetologia 2024-04-07
Incidence and progression of diabetic retinopathy in patients treated with glucagon-like peptide-1 receptor agonists versus sodium-glucose cotransporter 2 inhibitors: A population-based cohort study.
使用胰高血糖素樣肽-1受體激動劑與鈉-葡萄糖共轉運蛋白2抑制劑治療的患者中糖尿病視網膜病變的發生率和進展:一項基於人群的隊列研究。
Diabetes Obes Metab 2024-07-20
The Effect of Glucagon-Like Peptide-1 Receptor Agonists on Diabetic Retinopathy at a Tertiary Care Center.
在三級醫療中心中,Glucagon-Like Peptide-1 受體激動劑對糖尿病視網膜病變的影響。
Ophthalmol Sci 2024-08-14